Pharmaceutical developers are expanding clinical evaluations of GLP-1 and dual GIP/GLP-1 receptor agonists beyond primary diabetes and obesity treatments. Regulatory bodies are evaluating expanded label indications based on multi-center outcome trials.
Supply Chain and Manufacturing Expansion
Surging global demand has triggered unprecedented capital investment in peptide synthesis capacity and automated sterile fill-finish operations across major pharmaceutical production facilities.